KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Return on Sales (2018 - 2025)

Adaptive Biotechnologies' Return on Sales history spans 8 years, with the latest figure at 0.18% for Q4 2025.

  • For Q4 2025, Return on Sales rose 53.0% year-over-year to 0.18%; the TTM value through Dec 2025 reached 0.21%, up 68.0%, while the annual FY2025 figure was 0.21%, 68.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.18% at Adaptive Biotechnologies, down from 0.11% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.11% in Q3 2025 and bottomed at 6.21% in Q2 2023.
  • The 5-year median for Return on Sales is 1.1% (2024), against an average of 1.25%.
  • The largest annual shift saw Return on Sales crashed -502bps in 2023 before it soared 514bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 1.62% in 2021, then soared by 59bps to 0.66% in 2022, then tumbled by -129bps to 1.52% in 2023, then skyrocketed by 53bps to 0.71% in 2024, then skyrocketed by 75bps to 0.18% in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Return on Sales are 0.18% (Q4 2025), 0.11% (Q3 2025), and 0.43% (Q2 2025).